We are live on ! Find out more
PBA

Paradigm Biocapital Advisors Portfolio holdings

AUM $4.89B
1-Year Est. Return 251.12%
This Fund
S&P 500
This Quarter Est. Return
+36.12%
1 Year Est. Return
+251.12%
3 Year Est. Return
+670.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$750M
AUM Growth
+$249M
Cap. Flow
+$154M
Cap. Flow %
20.5%
Top 10 Hldgs %
62.56%
Holding
33
New
10
Increased
14
Reduced
4
Closed
5

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$32.8M
2
AXSM icon
Axsome Therapeutics
AXSM
+$26M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$24.6M
4
INCY icon
Incyte
INCY
+$16M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$14.1M

Top Sells

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$44.1M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$14.9M
3
ARVN icon
Arvinas
ARVN
+$11.3M
4
ENTA icon
Enanta Pharmaceuticals
ENTA
+$7.01M
5
UTHR icon
United Therapeutics
UTHR
+$5.03M

Sector Composition

Rank Sector Weight
1 Healthcare 94.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBT
1
DELISTED
Global Blood Therapeutics, Inc.
GBT
$80.1M 10.68%
1,175,879
-269,687
-19% -$14.9M
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$59.4M 7.92%
850,385
+190,417
+29% +$14.1M
INCY icon
3
Incyte
INCY
$23.5B
$51.5M 6.87%
773,082
+217,039
+39% +$16M
ASND icon
4
Ascendis Pharma A/S
ASND
$16.7B
$51.4M 6.85%
497,347
+65,177
+15% +$6.18M
LEGN icon
5
Legend Biotech
LEGN
$4.3B
$43.9M 5.86%
1,076,591
+97,995
+10% +$4.6M
BIIB icon
6
Biogen
BIIB
$29.9B
$41.3M 5.5%
+154,605
New +$32.8M
BIIB icon
7
CALL
Biogen
BIIB
$29.9B
$40M 5.34%
+150,000
New +$31.9M
IMCR icon
8
Immunocore
IMCR
$1.78B
$36.3M 4.84%
773,079
+105,662
+16% +$5.04M
VRDN icon
9
Viridian Therapeutics
VRDN
$2.13B
$33.6M 4.47%
1,636,211
+329,642
+25% +$5.93M
ARGX icon
10
argenx
ARGX
$57.4B
$31.9M 4.25%
90,297
+1,481
+2% +$549K
UTHR icon
11
United Therapeutics
UTHR
$26.3B
$29.4M 3.92%
140,561
-22,505
-14% -$5.03M
AKRO
12
DELISTED
Akero Therapeutics
AKRO
$28.4M 3.78%
+833,265
New +$12.7M
BCYC
13
Bicycle Therapeutics
BCYC
$270M
$27M 3.59%
1,158,686
+110,170
+11% +$2.62M
SNDX icon
14
Syndax Pharmaceuticals
SNDX
$1.84B
$26.1M 3.48%
1,085,142
+208,986
+24% +$4.69M
AXSM icon
15
Axsome Therapeutics
AXSM
$12.4B
$23.2M 3.09%
+520,080
New +$26M
HZNP
16
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$21.7M 2.9%
+351,405
New +$24.6M
ALPN
17
DELISTED
Alpine Immune Sciences Inc
ALPN
$15.9M 2.13%
2,214,722
+1,387,943
+168% +$11.4M
PRTA icon
18
Prothena Corp
PRTA
$458M
$14.3M 1.91%
+235,826
New +$7.46M
ARVN icon
19
Arvinas
ARVN
$518M
$12.6M 1.68%
283,777
-233,629
-45% -$11.3M
ESPR
20
DELISTED
Esperion Therapeutics
ESPR
$11.5M 1.54%
1,719,831
+311,781
+22% +$2.14M
MRUS
21
DELISTED
Merus
MRUS
$11.3M 1.51%
564,214
+111,970
+25% +$2.67M
GTHX
22
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$11M 1.47%
+884,574
New +$10.1M
CRNX icon
23
Crinetics Pharmaceuticals
CRNX
$8.86B
$10.2M 1.36%
+519,256
New +$10.6M
OYST
24
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$9.26M 1.24%
1,648,316
+314,986
+24% +$1.97M
TGTX icon
25
TG Therapeutics
TGTX
$8.58B
$8.91M 1.19%
1,505,479
-459,230
-23% -$3.01M
1
2

Similar funds

KCM
Kensico Capital Management Greenwich, Connecticut $4.9B AUM 41.26% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
FC
Freemont Capital Singapore $4.91B AUM 5.45% 1-Year Est. Return
WTC
WhitTier Trust Company Reno, Nevada $4.87B AUM 25.35% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
MSRPS
Maryland State Retirement & Pension System Baltimore, Maryland $4.92B AUM 28.48% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $4.93B AUM 12.22% 1-Year Est. Return

Paradigm Biocapital Advisors's Q3 2022 Portfolio in Review

As of Q3 2022, Paradigm Biocapital Advisors held 33 positions worth $750M, up 50% from $502M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Paradigm Biocapital Advisors deployed $154M of net new capital in Q3 2022, opening 10 new positions and adding to 14 existing holdings. Its largest new stake was Biogen: 154,605 shares worth $41.3M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Global Blood Therapeutics, Inc., an estimated $14.9M trimmed.

  • Paradigm Biocapital Advisors's largest Q3 2022 buy was Biogen: 154,605 shares worth $41.3M.
  • Paradigm Biocapital Advisors added most to Incyte in Q3 2022, an estimated $16M increase.
  • Paradigm Biocapital Advisors's biggest Q3 2022 reduction was Global Blood Therapeutics, Inc., cutting an estimated $14.9M.
  • Paradigm Biocapital Advisors fully exited Sierra Oncology, Inc. Common Stock in Q3 2022, selling an estimated $44.1M.
  • Paradigm Biocapital Advisors's ten largest holdings make up 63% of its $750M portfolio in Q3 2022.
  • Paradigm Biocapital Advisors opened 10 new positions and closed 5 in Q3 2022.
  • Paradigm Biocapital Advisors's portfolio value rose 50% quarter-over-quarter to $750M.

Based on Paradigm Biocapital Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.